These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 2353621)

  • 1. Effect of flosequinan (BTS 49465) on myocardial oxygen consumption.
    Greenberg S; Touhey B; Paul J
    Am Heart J; 1990 Jun; 119(6):1355-66. PubMed ID: 2353621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Positive inotropy contributes to the hemodynamic mechanism of action of flosequinan (BTS 49465) in the intact dog.
    Greenberg S; Touhey B
    J Cardiovasc Pharmacol; 1990 Jun; 15(6):900-10. PubMed ID: 1694912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hemodynamic and myocardial energetic effects of CK-3197, a selective positive inotropic agent.
    Greenberg S; Touhey B
    J Cardiovasc Pharmacol; 1991 Jan; 17(1):145-53. PubMed ID: 1708048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Positive inotropic and hemodynamic properties of flosequinan, a new vasodilator, and a sulfone metabolite.
    Falotico R; Haertlein BJ; Lakas-Weiss CS; Salata JJ; Tobia AJ
    J Cardiovasc Pharmacol; 1989 Sep; 14(3):412-8. PubMed ID: 2476620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential inotropic effects of flosequinan in ventricular muscle from normal ferrets versus patients with end-stage heart failure.
    Perreault CL; Hague NL; Loh E; Hunneyball IM; Sim MF; Morgan JP
    Br J Pharmacol; 1992 Jul; 106(3):511-6. PubMed ID: 1324072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of balanced vasodilator, flosequinan, on aortic impedance in failing heart.
    Yano M; Kohno M; Yamamoto T; Hisaoka T; Tanigawa T; Ono K; Lee B; Konishi M; Matsuzaki M
    J Cardiovasc Pharmacol; 1998 Sep; 32(3):466-70. PubMed ID: 9733361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Actions of the novel vasodilator, flosequinan, in isolated ventricular cardiomyocytes.
    Kelso EJ; McDermott BJ; Silke B
    J Cardiovasc Pharmacol; 1995 Mar; 25(3):376-86. PubMed ID: 7769801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure. Dose-response relationships and comparison to nitroprusside.
    Jaski BE; Fifer MA; Wright RF; Braunwald E; Colucci WS
    J Clin Invest; 1985 Feb; 75(2):643-9. PubMed ID: 3973022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of positive inotropic action of flosequinan, hydralazine, and milrinone on mammalian myocardium.
    Miao L; Perreault CL; Travers KE; Morgan JP
    Eur J Pharmacol; 1997 Feb; 321(2):201-8. PubMed ID: 9063689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Flosequinan, a new vasodilator: systemic and coronary hemodynamics and neuroendocrine effects in congestive heart failure.
    Cavero PG; De Marco T; Kwasman M; Lau D; Liu M; Chatterjee K
    J Am Coll Cardiol; 1992 Dec; 20(7):1542-8. PubMed ID: 1452928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of vasoactive intestinal peptide on myocardial contractility and coronary blood flow in the dog: comparison with isoproterenol and forskolin.
    Anderson FL; Kralios AC; Hershberger R; Bristow MR
    J Cardiovasc Pharmacol; 1988 Sep; 12(3):365-71. PubMed ID: 2464111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cardiovascular pharmacology of ICI 170777 ((6RS)-6-methyl-5-(pyrid-4-yl)-3H,6H-1,3,4- thiadiazin-2-one) a novel compound with positive inotropic and vasodilator effects.
    Collis MG; Keddie JR; Rouse W
    Br J Pharmacol; 1989 Jun; 97(2):409-18. PubMed ID: 2758224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies on the cardiac actions of flosequinan in vitro.
    Gristwood RW; Beleta J; Bou J; Cardelús I; Fernández AG; Llenas J; Berga P
    Br J Pharmacol; 1992 Apr; 105(4):985-91. PubMed ID: 1324061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of hyperosmotic mannitol on myocardial oxygen consumption.
    Vlahakes GJ; Powell WJ
    Am J Physiol; 1977 Oct; 233(4):H444-50. PubMed ID: 303055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Flosequinan: a vasodilator with positive inotropic activity.
    Corin WJ; Monrad ES; Strom JA; Giustino S; Sonnenblick ES; LeJemtel T
    Am Heart J; 1991 Feb; 121(2 Pt 1):537-40. PubMed ID: 1990760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of MCI-154, a cardiotonic agent, on regional contractile function and myocardial oxygen consumption in the presence and absence of coronary artery stenosis in dogs.
    Abe Y; Kitada Y; Narimatsu A
    J Pharmacol Exp Ther; 1993 May; 265(2):819-25. PubMed ID: 8496827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Positive inotropic and lusitropic effects of intravenous flosequinan in patients with heart failure.
    Burstein S; Semigran MJ; Dec GW; Boucher CA; Fifer MA
    J Am Coll Cardiol; 1992 Oct; 20(4):822-9. PubMed ID: 1527293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myocardial oxygen consumption during atrial pacing at various inotropic levels.
    Andersen FR; Ilebekk A; Kiil F
    Acta Physiol Scand; 1988 Jul; 133(3):315-24. PubMed ID: 3227926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of the role of the renin-angiotensin system in cardiac contractility utilizing the renin inhibitor remikiren.
    van Kats JP; Sassen LM; Danser AH; Polak MP; Soei LK; Derkx FH; Schalekamp MA; Verdouw PD
    Br J Pharmacol; 1996 Mar; 117(5):891-901. PubMed ID: 8851507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Dose-dependent effect of amrinone on hemodynamics, myocardial circulation and myocardial energy requirement. An experimental study].
    Veit S; Brückner JB; Vogt K; Wagner R; Hess W
    Z Kardiol; 1985 Feb; 74(2):76-84. PubMed ID: 3993153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.